- ISOINDOLINES AS HDAC INHIBITORS
-
The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs), having the formula: (I) wherein Z, X1, X2, Y1, Y2, Y3, L, Z, and R are described herein.
- -
-
Paragraph 00255
(2019/11/12)
-
- PIPERIDINE COMPOUNDS AS PCSK9 INHIBITORS
-
One aspect of the invention relates to a series of new PCSK9 inhibitor compounds comprising piperidine ring structures, including compounds of formula (I) and/or pharmaceutically acceptable salts thereof. Another aspect of the invention relates to methods of treating PCSK9 receptor related diseases comprising administration of one or more compounds of formula (I) or a pharmaceutically acceptable salt thereof.
- -
-
Paragraph 0373; 0378; 0379
(2018/11/21)
-
- HETEROCYCLIC COMPOUNDS AND USES THEREOF
-
Compounds and pharmaceutical compositions of formulae (I), (XI) and (XII) as PI3 kinase modulators and their use in the treatment of diseases such as cancer.
- -
-
Paragraph 00547
(2013/03/26)
-
- HETEROCYCLIC COMPOUNDS AND USES THEREOF
-
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
- -
-
Paragraph 00719; 00790
(2013/03/26)
-